The present study inadvertently found that FHND004, derived from the third-generation EGFR-TKI AZD9291 (Osimertinib) which is mainly for solid tumor NSCLC harboring EGFR-sensitive mutations, also has a strong inhibitory effect on the proliferation of MM cells. This evidence concerns the gene EGFR and Miyoshi myopathy.